EUCTR2011-000844-56-DE进行中（未招募）1 期
sTekinumab for the treatment Of Patients with active Ankylosing Spondylitis (TOPAS) – a 28-week, prospective, open-label, proof-of-concept study - TOPAS
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Age of =18 years.
- •2.Definite diagnosis of AS according to the modified New York criteria.
- •3.History of an inadequate response to =2 NSAIDs taken for at least 2 weeks each or NSAIDs intolerance/contraindication.
- •4.Active disease as defined by a BASDAI value of =4 at screening despite concomitant treatment with an NSAID or without NSAIDs in case of intolerance/contraindication.
- •5.Able and willing to give a written informed consent and comply with the requirements of the study protocol.
- •6.If female: either not of child-bearing potential (menopausal since 1 year or surgically sterile) or is willing and able to practice a reliable method of contraception throughout the study and 150 days after the last drug injection. Reliable methods of contraception are: condoms and other barrier methods, intrauterine devices, oral, parenteral or intravaginal contraceptives initiated at least 90 prior to screening, a vasectomised partner.
- •7.If male: either not of child-bearing potential (surgically sterilized, e.g. vasectomy) or is willing and able to practice a reliable method of contraception throughout the study and 150 days after the last drug injection.
- •8.If on NSAIDs: the dose must be stable for at least 2 weeks prior to baseline.
- •9.If on oral steroids: the dose must not exceed 10 mg (prednisolone equivalent) per day and must be stable for at least 4 weeks prior to baseline.
- •10.If on methotrexate: the dose must not exceed 25 mg per week and must be stable for at least 4 weeks prior to baseline, must be stable for 4 weeks prior to baseline.
- •11.If on analgesics: the dose must be stable for at least 2 weeks prior to baseline.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.The female subject is pregnant or lactating.
- •2.Patients with other chronic inflammatory articular disease or systemic autoimmune disease, e.g. systemic lupus erythematosus, Sjögren syndrome, rheumatoid arthritis, chronic fatigue syndrome (other manifestations of spondyloarthritis such as psoriasis, inflammatory bowel disease, arthritis, uveitis are not regarded as exclusion criteria).
- •3.History of inadequate response to previous anti-TNF a therapy. Patients who discontinued previous anti-TNF a therapy due to intolerability/side effects may participate in the study. This therapy must have been terminated at least 4 weeks prior to baseline if etanercept was used and at least 8 weeks if infliximab, adalimumab, or golimumab were used.
- •4.Previous treatment with biologics other than TNF a blockers.
- •5.Treatment with any other investigational drug within 4 weeks of 5 half-life of the drug (whichever is longer) prior to baseline.
- •6.Treatments with disease modifying anti-rheumatic drugs (DMARDs) other than methotrexate within 4 weeks prior to screening (8 weeks for leflunomide or 4 weeks with a standard cholestyramine wash-out).
- •7.Treatment with intravenous, intramuscular or intraarticular/periarticular steroids within 4 weeks prior to screening.
- •8.Any active current infection, a history of recurrent clinically significant infection, infections requiring treatment with antibiotics within 4 weeks prior to baseline.
- •9.Current clinical signs and symptoms suggestive for tuberculosis.
- •10.Positive QuantiFERON®-TB test at screening and/or abnormal chest x-ray (performed at screening or within 3 months prior to screening) suggestive for past or present tuberculosis (positive x-ray). Patients with a positive QuantiFERON®-TB test but negative chest x-ray and without clinical symptoms suggestive for tuberculosis may participate in the study after initiation of standard prophylactic antimycobacterial treatment.
- •11.Chronic infection with hepatitis B or C, history of HIV infection.
- •12.Primary or secondary immunodeficiency.
- •13.Actual malignancies or history of malignancies with curative treatment within 5 years prior to screening, except successfully treated non-metastatic squamous-cell or basal-cell carcinoma or carcinoma in situ of the cervix.
- •14.Evidence of severe uncontrolled gastrointestinal, hepatic, renal, pulmonary, cardiovascular, nervous or endocrine disorders.
- •15.Any other conditions making the patient unsuitable in the opinion of the investigator for the participation in the current study.
- •16.Patients with a history of a severe psychiatric illness, which might interfere with the patient's ability to understand the requirements of the study and assessment.
- •17.Diagnosis of fibromyalgia.
- •18.Alcohol abuse or illegal drug consume in the last 12 months.
- •19.Vaccination with a live vaccine within 12 weeks prior to baseline.
- •20.Known hypersensitivity to any component of the study medication.
- •21.Any of the following laboratory abnormalities as detected at screening:
- •o Haemoglobin < 8.5 g/dl
- •o Neutrophil counts < 2.000 / µl
- •o Platelet count < 125.000 / µl
- •o Serum creatinine > 1.4 mg/dl for women or 1.6 mg/dl for men.
- •o Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) or alkaline phosphatase (AP) or gamma-glutamyl-transpeptidase (GGT) >3 times upper limit of normal
研究者
相似试验
招募中
不适用
IFI-ED ustekinumab in patients with ulcerative colitis long term on extended follow upOral and Gastrointestinal - Inflammatory bowel diseaseulcerative colitisACTRN12622001332718Concord Repatriation General Hospital20
已完成
2 期
Ustekinumab for the Treatment of Patients With Active Ankylosing SpondylitisAnkylosing SpondylitisNCT01330901Charite University, Berlin, Germany22
进行中（未招募）
1 期
Adalimumab s.c. for the treatment of patients with hidradenitis suppurativa – clinical efficacy, safety and tolerability - SOPHISTICATE - SOPHISTICATEPatients with hidradenitis suppurativaMedDRA version: 8.1Level: LLTClassification code 10020041Term: Hidradenitis suppurativaEUCTR2006-005297-48-DKniversity of Copenhagen, Roskilde, Department of Dermatology
招募中
1 期
Multi-drug treatment for breast cancer patients with brain metastasesCTIS2024-510703-11-00nicancer55
招募中
不适用
intedanib treatment for the patients with systemic scleroderma-associated interstitial lung disease-a prospective observational studyJPRN-UMIN000039605Department of Respiratory Medicine, Juntendo University Hospital100